Geron Corporation

Case Overview
27 Days Left to Seek Lead Plaintiff
Lead Plaintiff Deadline: | Lead Plaintiff Deadline: 05/12/2025 |
Status: | Status: Investigating |
Company Name: | Company Name: Geron Corporation |
Court: | Court: Northern District of California |
Case Number: | Case Number: 3:25cv02507 |
Class Period: | Class Period: 02/28/2024 - 02/25/2025 |
Ticker: | Ticker: GERN |
Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of those who acquired Geron Corporation (“Geron” or the “Company”) (NASDAQ:GERN) securities during the period from February 28, 2024, through February 25, 2025 (“the Class Period”). Investors have until May 12, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit.
On February 26, 2025, Geron announced its financial results for the fourth quarter of fiscal 2024, disclosing that growth for Rytelo, the Company’s lead product candidate, had flattened over the preceding months. The Company attributed the diminished growth on seasonality, competition, lack of awareness for Rytelo, and the burden of the monitoring requirement necessary for the drug treatment. On this news, the price of Geron shares declined by $0.76 per share, from $2.37 per share on February 25, 2025, to close at $1.61 on February 26, 2025.
The complaint alleges that defendants, throughout the Class Period, failed to disclose material information concerning expectations for the launch and growth potential of Rytelo.
On February 26, 2025, Geron announced its financial results for the fourth quarter of fiscal 2024, disclosing that growth for Rytelo, the Company’s lead product candidate, had flattened over the preceding months. The Company attributed the diminished growth on seasonality, competition, lack of awareness for Rytelo, and the burden of the monitoring requirement necessary for the drug treatment. On this news, the price of Geron shares declined by $0.76 per share, from $2.37 per share on February 25, 2025, to close at $1.61 on February 26, 2025.
The complaint alleges that defendants, throughout the Class Period, failed to disclose material information concerning expectations for the launch and growth potential of Rytelo.